These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30179749)

  • 1. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing potential HDAC3 inhibitors to improve memory and learning.
    Amin SA; Adhikari N; Jha T; Ghosh B
    J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
    Abdizadeh T; Ghodsi R; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
    Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
    J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
    Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
    Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
    Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
    Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand release mechanisms and channels in histone deacetylases.
    Kalyaanamoorthy S; Chen YP
    J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
    Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
    J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
    Adhikari N; Jha T; Ghosh B
    J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors.
    Mahipal ; Tanwar OP; Karthikeyan C; Moorthy NS; Trivedi P
    Med Chem; 2010 Sep; 6(5):277-85. PubMed ID: 20977417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
    Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
    Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.